Scarica l'app Stockscreener
131.26
0.49%
-0.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novartis Ag Adr Borsa (NVS) Ultime notizie
Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028 - Benzinga
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis announces expiration of Tourmaline Bio tender offer - Novartis
Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com
Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm
Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news
Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis
Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
Should You Buy Novartis Stock Before October 28? - Barchart.com
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance (NYSE:NVS) - Seeking Alpha
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva
Pharma's Direct-To-Patient Wave Hits Novartis Next - Sahm
0.01%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):